Evidence map›Paper›PMID 36929244›Full record

ArticleNeuropsychopharmacology reports2023

A case study of the utilization of clozapine treatment for treatment-resistant schizophrenia associated with 22q11.2 deletion syndrome.

Arisa Tsurue, Hideki Funahashi, Keiichi Tsurue, Masahiko Kawano, Yasushi Ishida, Yoji Hirano

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuropsychopharmacology reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Arisa TsurueMiyakonojo Shinsei Hospital, Miyakonojo, Japan.
Hideki FunahashiDepartment of Psychiatry, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
Keiichi TsurueMiyakonojo Shinsei Hospital, Miyakonojo, Japan.
Masahiko KawanoMiyakonojo Shinsei Hospital, Miyakonojo, Japan.
Yasushi IshidaDepartment of Psychiatry, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
Yoji HiranoDepartment of Psychiatry, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.ORCID 0000-0001-6847-9677
University of Miyazaki · JPNational Institute of Technology, Miyakonojo College · JP

Funding

This research was supported in part by JSPS KAKENHI JP20KK0193 (YH) and JP21H02851 (YH)
6 · The paper itself

Abstract

backgroundThe optimal treatment strategy for patients with treatment-resistant schizophrenia (TRS) associated with 22q11.2 deletion syndrome (DS) remains a subject of debate. CASE PRESENTATION: We present the case of a 40-year-old female patient diagnosed with TRS and 22q11.2DS who was effectively treated with clozapine. She was diagnosed with schizophrenia and mild intellectual disability during her adolescence; despite being hospitalized for a period of 10 years beginning in her 30s, she continued to exhibit symptoms of impulsivity, and explosive behavior, requiring periods of isolation. We ultimately decided to switch her medication to clozapine, which was administered with caution and gradually titrated upward, with no discernable adverse effects, resulting in a marked improvement in her symptoms and obviated the need for isolation. Subsequently, the patient's history of congenital heart disease and facial abnormalities prompted initial suspicions of a 22q11.2DS diagnosis, which was subsequently confirmed through genetic testing.

conclusionClozapine may serve as an efficacious pharmacological intervention for TRS patients with 22q11.2DS, including those of Asian descent.

Indexed as

ClozapineDiGeorge SyndromeSchizophreniaAdolescentAdultFemaleGenetic TestingHumansSchizophrenia, Treatment-ResistantClozapine22q11.2 deletion syndromeAsianclozapinetreatment-resistant schizophrenia

Identifiers

PMID36929244
PMCPMC10275284
OpenAlexW4327554142

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.